Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced it will report financial results and operational highlights for the second quarter of 2026 before hosting a conference call and webcast at 8:30 a.m. ET on Aug. 10, 2026. The announcement provides investors with an opportunity to gain insights into the company's recent performance and strategic developments, particularly following the approval of its flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years.
A replay of the webcast will be available in the Investors section of the company's website following the event. The call comes as Tonix continues to expand its commercial infrastructure for central nervous system (CNS) treatments, including its acute migraine products Zembrace® SymTouch® and Tosymra®. The company is also maximizing the science behind TONMYA through Phase 2 clinical trials evaluating its potential in major depressive disorder and acute stress disorder.
Beyond its CNS portfolio, Tonix is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Additionally, TNX-2900 is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. These programs underscore Tonix's commitment to addressing areas of high unmet medical need.
The financial results call will provide detailed updates on these initiatives and the company's overall financial health. Investors can access the press release and additional information on the Tonix website. For the full press release, visit https://ibn.fm/A9CfR. For the latest news and updates relating to TNXP, visit the company's newsroom at https://ibn.fm/TNXP.
